{
    "clinical_study": {
        "@rank": "142806", 
        "acronym": "AC105", 
        "arm_group": [
            {
                "arm_group_label": "Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients randomized (1:1) to the placebo arm will receive an initial intravenous infusion of saline for 30 minutes within a pre-specified time window (12, 9, 6 hours post-injury). Patients will receive 5 additional infusions of the same dose and duration at 6 -hour intervals."
            }, 
            {
                "arm_group_label": "AC105", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients randomized (1:1) to the active drug arm will receive an initial intravenous infusion of AC105 for 30 minutes within a pre-specified time window (12, 9, 6 hours post-injury). Patients will receive 5 additional infusions of the same dose and duration at 6 -hour intervals."
            }
        ], 
        "brief_summary": {
            "textblock": "To determine safety and tolerability of AC105 following a regimen of 6 intravenous doses\n      over 30 hours in patients with acute non-penetrating traumatic spinal cord injury (SCI)."
        }, 
        "brief_title": "A Study of AC105 in Patients With Acute Traumatic Spinal Cord Injury", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Spinal Cord Injury", 
        "condition_browse": {
            "mesh_term": [
                "Spinal Cord Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female between 18 and 65 years of age, inclusive\n\n          -  Acute traumatic SCI, at a neurological level between C4 and T11\n\n          -  No evidence of penetrating or transection injury (e.g. caused by projectile or stab\n             wound)\n\n          -  Neurological ASIA Impairment Scale A, B or C\n\n          -  Patient is able to provide written or verbal witnessed consent. If unable to provide\n             either, consent may be provided by legally authorized representative (LAR)\n\n          -  Patient is able to initiate treatment within time window of injury\n\n        Exclusion Criteria:\n\n          -  Known allergy or hypersensitivity to polyethylene glycol\n\n          -  Mental impairment or other conditions that would preclude a reliable ASIA exam or\n             adequate consent\n\n          -  Positive urine pregnancy test result\n\n          -  Serum creatinine level \u2265 2 mg/dL\n\n          -  History or active renal failure or dialysis\n\n          -  Mean arterial blood pressure < 60 mmHg despite vasopressor treatment\n\n          -  On a current regimen of digoxin\n\n          -  Chronic use of magnesium salts prior to the SCI (within 1week of presentation) and/or\n             the use of magnesium salts in the acute care setting prior to the administration of\n             investigational product\n\n          -  Any other medical condition that, in the judgment of the investigator, would preclude\n             provision of informed consent, make participation in the study unsafe, or\n             unreasonably complicate follow-up or the interpretation of study outcome data or may\n             otherwise interfere with achieving the study objectives\n\n          -  In the judgment of the Investigator, cannot adequately provide informed consent, is\n             likely to be non-compliant, or may be unable to cooperate with study requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01750684", 
            "org_study_id": "ACPM-SI-1009"
        }, 
        "intervention": [
            {
                "arm_group_label": "AC105", 
                "intervention_name": "AC105", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Saline", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Acute", 
            "Traumatic", 
            "SCI", 
            "Spinal Cord Injury"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Double-blind, Randomized, Placebo-controlled Study to Determine the Safety, Tolerability and Potential Activity of AC105 Following a Regimen of 6 Doses Over 30 Hours in Patients With Acute Traumatic Spinal Cord Injury (SCI) as Compared to Patients Treated With Placebo.", 
        "overall_official": {
            "affiliation": "Acorda Therapeutics", 
            "last_name": "Andrew Eisen, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All adverse events reported by the patient or observed by the study personnel from the time informed consent is obtained and up to the patient's study completion or discontinuation will be recorded on the Adverse Event Case Report Form.", 
            "measure": "Safety and tolerability assessed by comparing adverse event (AE) data for patients administered a regimen of 6 intravenous doses of AC105 over 30 hours compared with patients administered the same regimen of placebo.", 
            "safety_issue": "No", 
            "time_frame": "up to 6 months"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01750684"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Measuring Maximum Measured Plasma Concentration (Cmax), Time to Maximum Measured Plasma Concentration (Tmax), Half-life calculated as In(2)/kel (T 1/2) and Area Under the Plasma Concentration versus time curve (AUC).", 
            "measure": "Pharmacokinetic (PK) parameters of AC105 using individual patient plasma concentration-time data", 
            "safety_issue": "No", 
            "time_frame": "baseline, prior to and up to 5 hours following last infusion"
        }, 
        "source": "Acorda Therapeutics", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Department of Defense", 
                    "agency_class": "U.S. Fed"
                }, 
                {
                    "agency": "DP Clinical, Inc.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Acorda Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}